SE9904750D0 - New formulation, use and method - Google Patents

New formulation, use and method

Info

Publication number
SE9904750D0
SE9904750D0 SE9904750A SE9904750A SE9904750D0 SE 9904750 D0 SE9904750 D0 SE 9904750D0 SE 9904750 A SE9904750 A SE 9904750A SE 9904750 A SE9904750 A SE 9904750A SE 9904750 D0 SE9904750 D0 SE 9904750D0
Authority
SE
Sweden
Prior art keywords
disorders
disorder
reboxetine
prodrugs
metabolites
Prior art date
Application number
SE9904750A
Other languages
Swedish (sv)
Inventor
Ulla Hoeck
Bo Kreilgaard
Helle Kristensen
Original Assignee
Pharmacia & Upjohn Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Ab filed Critical Pharmacia & Upjohn Ab
Priority to SE9904750A priority Critical patent/SE9904750D0/en
Publication of SE9904750D0 publication Critical patent/SE9904750D0/en
Priority to PCT/SE2000/001972 priority patent/WO2001047503A1/en
Priority to EP00971947A priority patent/EP1244431A1/en
Priority to AU10681/01A priority patent/AU1068101A/en
Priority to ARP000105838A priority patent/AR026371A1/en
Priority to PE2000001219A priority patent/PE20011024A1/en
Priority to MYPI20006094A priority patent/MY133485A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Device for transdermal administration of reboxetine, optionally encompassing salts, prodrugs and metabolites thereof, to the use of reboxetine, optionally encompassing salts, prodrugs and metabolites thereof, method for the manufacturing of a medicament to be administered transdermally, and methods of treating depression and/or symptoms associated with this condition and/or for treating addictive disorders and withdrawal syndromes, adjustment disorders, age-associated learning and mental disorders, anorexia nervosa, apathy, attention-deficit disorders due to general medical conditions, attention-deficit hyperactivity disorders, bipolar disorders, bulimia nervosa, chronic fatigue syndrome, conduct disorders, cyclothymic disorders, depression, dysthymic disorders, fibromyalgia and other somatoform disorders, stress incontinence, generalized anxiety disorders, inhalation disorders, an intoxication disorders, obesity, obsessive compulsive disorders and related spectrum disorders, oppositional defiant disorders, panic disorder, peripheral neuropathy, post-traumatic stress disorder, premenstrual dysphoric disorder, psychotic disorders, seasonal affective disorder, sleep disorder, social phobia, specific developmental disorders and selective serotonin reuptake inhibition (SSRI) "poop out" syndrome and symptoms associated with these conditions, and/or for obtaining an anti-reserpine and/or noradrenaline reuptake inhibiting effect by transdermal administration of reboxetine, optionally encompassing salts, prodrugs and metabolites thereof.
SE9904750A 1999-12-23 1999-12-23 New formulation, use and method SE9904750D0 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
SE9904750A SE9904750D0 (en) 1999-12-23 1999-12-23 New formulation, use and method
PCT/SE2000/001972 WO2001047503A1 (en) 1999-12-23 2000-10-12 Transdermal administration of reboxetine
EP00971947A EP1244431A1 (en) 1999-12-23 2000-10-12 Transdermal administration of reboxetine
AU10681/01A AU1068101A (en) 1999-12-23 2000-10-12 Transdermal administration of reboxetine
ARP000105838A AR026371A1 (en) 1999-12-23 2000-11-06 NEW FORMULATION, USE AND METHOD
PE2000001219A PE20011024A1 (en) 1999-12-23 2000-11-15 REBOXETIN TRANSDERMAL DEVICE, USE AND METHOD
MYPI20006094A MY133485A (en) 1999-12-23 2000-12-21 Transdermal administration of reboxetine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9904750A SE9904750D0 (en) 1999-12-23 1999-12-23 New formulation, use and method

Publications (1)

Publication Number Publication Date
SE9904750D0 true SE9904750D0 (en) 1999-12-23

Family

ID=20418276

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9904750A SE9904750D0 (en) 1999-12-23 1999-12-23 New formulation, use and method

Country Status (7)

Country Link
EP (1) EP1244431A1 (en)
AR (1) AR026371A1 (en)
AU (1) AU1068101A (en)
MY (1) MY133485A (en)
PE (1) PE20011024A1 (en)
SE (1) SE9904750D0 (en)
WO (1) WO2001047503A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1629843A3 (en) * 1999-07-01 2006-03-15 Pharmacia & Upjohn Company LLC Reboxetine for treating chronic fatigue syndrome
ATE305307T1 (en) 1999-07-01 2005-10-15 Pharmacia & Upjohn Co Llc REBOXETINE FOR THE TREATMENT OF MIGRAINE HEADACHE
US20030082225A1 (en) * 2001-10-19 2003-05-01 Mason Paul Arthur Sterile, breathable patch for treating wound pain
EP2338873A1 (en) 2009-12-22 2011-06-29 Gmeiner, Peter New aminotetraline derivatives
TWI754702B (en) 2016-12-28 2022-02-11 德商Ｕｃｂ製藥有限公司 (aza)indole- and benzofuran-3-sulfonamides
DE102017127433A1 (en) * 2017-11-21 2019-05-23 Lts Lohmann Therapie-Systeme Ag TTS based on adhesive plasticizer polymer matrices
US20190381056A1 (en) 2018-06-17 2019-12-19 Axsome Therapeutics, Inc. Compositions for delivery of reboxetine
TW202016088A (en) 2018-06-19 2020-05-01 德商Ｕｃｂ製藥有限公司 Pyridinyl and pyrazinyl-(aza)indolsulfonamides
EP3584244A1 (en) 2018-06-20 2019-12-25 UCB Pharma GmbH Substituted alkoxypyridinyl indolsulfonamides
US20200147093A1 (en) 2018-10-15 2020-05-14 Axsome Therapeutics, Inc. Use of esreboxetine to treat nervous system disorders such as fibromyalgia
ES2969383T3 (en) 2019-06-17 2024-05-17 Ucb Pharma Gmbh N-(phenyl)-indole-3-sulfonamide derivatives and related compounds as modulators of GPR17 for the treatment of CNS disorders such as multiple sclerosis

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999011208A1 (en) * 1997-08-28 1999-03-11 Williams C Donald Method and composition for transdermal administration of pharmacologic agents

Also Published As

Publication number Publication date
PE20011024A1 (en) 2001-10-03
AR026371A1 (en) 2003-02-05
WO2001047503A1 (en) 2001-07-05
EP1244431A1 (en) 2002-10-02
MY133485A (en) 2007-11-30
AU1068101A (en) 2001-07-09

Similar Documents

Publication Publication Date Title
SE9904750D0 (en) New formulation, use and method
EA200801488A1 (en) SUBSTITUTED PHENETHYLAMINES OWNING SEROTONINERGIC AND / OR NOREPINEFININERGIC ACTIVITY
RS20120158A3 (en) Phenyl-piperazine derivatives as serotonin reuptake inhibitors
CY1124111T1 (en) GLUTAMATE REGULATORS IN THE TREATMENT OF MENTAL DISORDERS
NO20055208L (en) 4- (2-Phenylsulfanyl-phenyl) -piperidine derivatives as serotonin reuptake inhibitors
ECSP16003103A (en) HETEROAROMATIC COMPOUNDS AND THEIR USE AS D1 LIGANDS OF DOPAMINE
JP2006143749A5 (en)
NI201500066A (en)
ATE410163T1 (en) METHOD FOR THE TREATMENT AND DIAGNOSIS OF SLEEP BREATHING DISORDERS USING ZONISAMIDE AND MEANS FOR IMPLEMENTING THE METHOD
UA102379C2 (en) 7-azaindole derivatives as selective inhibitors of the beta-hydroxysteroiddehydrogenase type 1
ATE459353T1 (en) GABOXADOL USED TO TREAT DEPRESSION AND OTHER AFFECTIVE DISORDERS
NO20055206L (en) 4- (2-phenyloxyphenyl) -piperidine or -1,2,3,6-tetrahydropyridine derivatives as serotonin reuptake inhibitors
RU2004112546A (en) PARTIAL AGONISTIC ACTIVITY AGAINST D2 DOPAMINE RECEPTORS AND / OR NORADRENALIN INHIBITING ACTIVITY
WO2007058998A3 (en) Substituted phenylpiperidines with serotoninergic activity and enhanced therapeutic properties
EA200101110A1 (en) NEW PHARMACEUTICAL COMBINATIONS OF NOS INHIBITORS
DK1392700T3 (en) Antidepressant azaheterocyclyl methyl derivatives of 7,8-dihydro-1,6,9-trioxa-3-aza-cyclopenta [a] naphthalene
ATE334989T1 (en) ANTIDEPRESSIVE AZAHETEROCYCLYLMETHYL DERIVATIVES OF 2,3-DIHYDRO-1,4-DIOXINO 2,3-FÖCHINOXALINE
MXPA05010678A (en) 4-(2-phenylsulfanyl-phenyl)-1,2,3,6-tetrahydropyridine derivatives as serotonin reuptake inhibitors.
DE60312874D1 (en) COMBINATION THERAPY USING A SEROTONIN RECIPROCAL HEATER
TW200507853A (en) Use of s-10-hydroxy-10,11-dihydro-carbamazepine for the treatment of anxiety and bipolar disorders
EA201070736A1 (en) 4- [2,3-DIFFOR-6- (2-Fluoro-4-Methylphenylsulfanyl) phenyl] piperidine
NO20005621L (en) New drug combinations
NO20085172L (en) 3- (1H-indol-3-yl) indan-1-ylamine derivatives for the treatment of depression and anxiety
CY1116959T1 (en) Substituted PHAs with serotoninergic and / or Norepinephrine activity
ATE423772T1 (en) MORPHOLINE DERIVATIVES AS INHIBITORS OF NOREPINEPHRINE REUPSTRUCTION